Clioquinol shortage — AU supply status & alternatives

Clioquinol

ATC D08AH30

In shortage · Australia

LOCACORTEN-VIOFORM ear drops bottle

In declared shortage · 🇦🇺 Australia

Critical shortage

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

Sept 2026

Sponsor est. via TGA

Product attributes reference data we hold

ATC level 4
Active ingredient (INN)	Clioquinol
Brand names	LOCACORTEN-VIOFORM ear drops bottle
ATC level 5	D08AH30

Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper

Controlled substance	No

Marketing-authorisation holders	CHEMIDEX PHARMA LIMITED, AMDIPHARM UK LIMITED, PHARMASCIENCE INC

Registrations on file	3

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇪🇸 ES

€1.59

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders3 registrations · 3 MA holders

Product	Strength	Form	Market	MA holder	Status
Betamethasone Valerate/Clioquinol	1 MG	cream	🇬🇧 GB	CHEMIDEX PHARMA LIMITED	Active
Flumetasone/Clioquinol 0.02% W/V / 1% W/V Ear Drops	0.02%	solution	🇬🇧 GB	AMDIPHARM UK LIMITED	Active
Pms-Flumethasone-Clioquinol	—	drops	🇨🇦 CA	PHARMASCIENCE INC	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.